

CLAIMS

1. A compound of Formula I
N,6-dimethyl-3-(2*H*-1,2,3-triazol-2-yl)-*N*-[(2*S*)-1-[[5-(trifluoro methyl)pyrazin-2-yl]amino]propan-2-yl]pyridine-2-carboxamide;
N,6-dimethyl-3-(2*H*-1,2,3-triazol-2-yl)-*N*-[(2*S*)-1-[[5-(trifluoro methyl)pyrimidin-2-yl]amino]propan-2-yl]pyridine-2-carboxamide;
 or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1, wherein
N,6-dimethyl-3-(2*H*-1,2,3-triazol-2-yl)-*N*-[(2*S*)-1-[[5-(trifluoro methyl)pyrazin-2-yl]amino]propan-2-yl]pyridine-2-carboxamide;
 or a pharmaceutically acceptable salt or solvate thereof.
3. A compound according to claim 1 or claim 2, wherein
N,6-dimethyl-3-(2*H*-1,2,3-triazol-2-yl)-*N*-[(2*S*)-1-[[5-(trifluoro methyl)pyrimidin-2-yl]amino]propan-2-yl]pyridine-2-carboxamide;
 or a pharmaceutically acceptable salt or solvate thereof.
4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.
5. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy.
6. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for treating schizophrenia and other psychotic disorders (e.g., psychotic disorder, psychosis or schizoaffective disorder); dementia and other cognitive disorders; anxiety disorders (e.g., generalized anxiety disorder, post-traumatic stress disorder, panic disorders, acute stress disorder, social anxiety disorder, phobias including agoraphobia, obsessive compulsive disorder, trichotillomania or body dysmorphic disorder); mood disorders (e.g., depressive disorders, major depressive disorders, bipolar disorders including bipolar I and II, bipolar mania, bipolar depression); addiction including substance dependence (e.g. cocaine, opiates, cannabis or prescription drug dependence), alcohol dependence, nicotine dependence or gambling disorder; eating

- disorders (e.g. binge eating, bulimia nervosa, anorexia nervosa or obesity); sleep disorders (e.g. rapid eye movement sleep disorder); disorders usually first diagnosed in infancy, childhood, or adolescence (e.g., attention-deficit disorder, autistic spectrum disorders, Rett syndrome, Fragile X syndrome, Asperger syndrome and disruptive behaviour disorders); restless leg syndrome; pain (e.g. neuropathic pain including chemotherapy induced pain or migraine); osteoporosis and neurodegenerative disorders (e.g. Parkinson's or Alzheimer's disease).
- 5